Song-Bai Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Song-Bai Liu has a total of 440 co-authors. Here are the top co-authors by number of shared publications:
- Sheng-Li Xue
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
17 shared publications Jiahui Du
Jiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control, Suzhou Vocational Health College
13 shared publications- Qiao-Cheng Qiu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University
6 shared publications - Binghui Shen
Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope, Duarte, USA
5 shared publications - Hai-Ping Dai
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
5 shared publications Yuan-Hong Huang
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University
5 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Wiley in Advanced Science
- p. e77762
Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis
Isocitrate dehydrogenase 3 alpha (IDH3A) is a key rate‐limiting enzyme in the tricarboxylic acid (TCA) cycle, traditionally associated with cellular energy metabolism. However, its role in cancer remains incompletely understood. Here, we demonstrate that IDH3A is significantly overexpressed in melanoma, primarily due to DNA copy number amplification. Metabolomic analysis revealed that IDH3A overexpression enhanced multiple biosynthetic intermediates, including G6P, F6P, DHAP, and 6‐phosphogluconate, indicating metabolic reprogramming toward anabolic processes without significantly affecting ATP or lactate production. Intriguingly, IDH3A localizes to the nucleus in melanoma cells and promotes tumorigenesis independent of its dehydrogenase activity. Nuclear IDH3A interacts with transcription factor YBX1, enriching at promoter regions of oncogenes such as c‐FOS and c‐JUN, thereby suppressing apoptosis and promoting tumor growth. Furthermore, we identify NONO as a nuclear chaperone that facilitates the nuclear localization of IDH3A through direct interaction, primarily involving NONO amino acids Q166 and S207. Disruption of NONO impairs IDH3A nuclear translocation and mitigates its tumor‐promoting function. Collectively, our findings uncover a noncanonical role of IDH3A as a nuclear regulator of transcription via YBX1, offering novel insight into metabolic enzyme reprogramming in melanoma.
- 11 September 2026
- Published by Wiley in Advanced Science
- p. e77762
Open AccessNuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis
Isocitrate dehydrogenase 3 alpha (IDH3A) is a key rate‐limiting enzyme in the tricarboxylic acid (TCA) cycle, traditionally associated with cellular energy metabolism. However, its role in cancer remains incompletely understood. Here, we demonstrate that IDH3A is significantly overexpressed in melanoma, primarily due to DNA copy number amplification. Metabolomic analysis revealed that IDH3A overexpression enhanced multiple biosynthetic intermediates, including G6P, F6P, DHAP, and 6‐phosphogluconate, indicating metabolic reprogramming toward anabolic processes without significantly affecting ATP or lactate production. Intriguingly, IDH3A localizes to the nucleus in melanoma cells and promotes tumorigenesis independent of its dehydrogenase activity. Nuclear IDH3A interacts with transcription factor YBX1, enriching at promoter regions of oncogenes such as c‐FOS and c‐JUN, thereby suppressing apoptosis and promoting tumor growth. Furthermore, we identify NONO as a nuclear chaperone that facilitates the nuclear localization of IDH3A through direct interaction, primarily involving NONO amino acids Q166 and S207. Disruption of NONO impairs IDH3A nuclear translocation and mitigates its tumor‐promoting function. Collectively, our findings uncover a noncanonical role of IDH3A as a nuclear regulator of transcription via YBX1, offering novel insight into metabolic enzyme reprogramming in melanoma.
- Open Access
- 14 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
EIF4EBP1 in Breast Cancer: Translational Control, Regulatory Networks, and Therapeutic Frontiers
Eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1/4E-BP1) is a pivotal translational regulator with context-dependent roles in breast cancer pathogenesis. Its phosphorylation status, dynamically controlled by mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and AMP-activated protein kinase (AMPK) signaling, dictates a dualistic function: hypophosphorylated EIF4EBP1 suppresses oncogenesis by sequestering eIF4E and inhibiting cap-dependent translation of pro-tumorigenic mRNAs (e.g., cyclin D1 and c-MYC), while hyperphosphorylation promotes tumor progression and therapeutic resistance. EIF4EBP1 amplification (8p11-p12) is correlated with endocrine resistance and poor prognosis. EIF4EBP1 modulates cell cycle checkpoints, metabolic adaptation under stress, and resistance to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and rapalogs via feedback loops (e.g., SGK3/Akt reactivation). Emerging therapeutic strategies, such as ATP-competitive mTOR inhibitors, bisteric compounds, and agents targeting polyamine metabolism or upstream kinases, exploit the dynamics of EIF4EBP1 phosphorylation. As a biomarker, phosphorylated EIF4EBP1 levels predict tumor aggressiveness and treatment failure, positioning it as a critical node for precision oncology. Future research must address spatial heterogeneity and leverage multi-omics/AI-driven approaches.
- 14 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Open AccessEIF4EBP1 in Breast Cancer: Translational Control, Regulatory Networks, and Therapeutic Frontiers
Eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1/4E-BP1) is a pivotal translational regulator with context-dependent roles in breast cancer pathogenesis. Its phosphorylation status, dynamically controlled by mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and AMP-activated protein kinase (AMPK) signaling, dictates a dualistic function: hypophosphorylated EIF4EBP1 suppresses oncogenesis by sequestering eIF4E and inhibiting cap-dependent translation of pro-tumorigenic mRNAs (e.g., cyclin D1 and c-MYC), while hyperphosphorylation promotes tumor progression and therapeutic resistance. EIF4EBP1 amplification (8p11-p12) is correlated with endocrine resistance and poor prognosis. EIF4EBP1 modulates cell cycle checkpoints, metabolic adaptation under stress, and resistance to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and rapalogs via feedback loops (e.g., SGK3/Akt reactivation). Emerging therapeutic strategies, such as ATP-competitive mTOR inhibitors, bisteric compounds, and agents targeting polyamine metabolism or upstream kinases, exploit the dynamics of EIF4EBP1 phosphorylation. As a biomarker, phosphorylated EIF4EBP1 levels predict tumor aggressiveness and treatment failure, positioning it as a critical node for precision oncology. Future research must address spatial heterogeneity and leverage multi-omics/AI-driven approaches.
- 28 July 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 233
Construction of Human Breast Cancer Organoids and Comet Assay–Based Quantification of Doxorubicin-Induced DNA Damage
Breast cancer is the most common malignancy among women worldwide and exhibits substantial heterogeneity. Doxorubicin (DOX) is widely used in breast cancer treatment, and its primary mechanism of action involves inducing DNA double-strand breaks and triggering cell death. In this protocol, a human BCO model was established to quantitatively assess DOX-induced DNA damage. Primary breast cancer cells were isolated from patient-derived tumor tissues through mechanical and enzymatic dissociation and subsequently cultured in a three-dimensional matrix to generate BCOs. Organoids were then treated with 8 μM DOX for 2 h. DNA damage was evaluated after 2 h of treatment. Following treatment, organoids were dissociated into single cells, embedded in low-melting-point agarose, and electrophoresed under alkaline conditions. Following electrophoresis, DNA migration patterns were visualized as comet structures under fluorescence microscopy and quantitatively analyzed using OpenComet software to determine the percentage of tail DNA (% Tail DNA). The comet assay successfully detected DNA damage in BCOs. Compared to the control group, BCOs exposed to 8 μM DOX for 2 h exhibited elongated comet tails following organoid dissociation and electrophoresis. Quantitative analysis revealed that the percentage of tail DNA was significantly higher in the treated group, indicating the induction of DNA damage. This highly sensitive method supports toxicological and pharmacodynamic studies of DOX and provides a robust technical platform for assessing DNA damage in patient-derived BCO systems.
- 28 July 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 233
Construction of Human Breast Cancer Organoids and Comet Assay–Based Quantification of Doxorubicin-Induced DNA Damage
Breast cancer is the most common malignancy among women worldwide and exhibits substantial heterogeneity. Doxorubicin (DOX) is widely used in breast cancer treatment, and its primary mechanism of action involves inducing DNA double-strand breaks and triggering cell death. In this protocol, a human BCO model was established to quantitatively assess DOX-induced DNA damage. Primary breast cancer cells were isolated from patient-derived tumor tissues through mechanical and enzymatic dissociation and subsequently cultured in a three-dimensional matrix to generate BCOs. Organoids were then treated with 8 μM DOX for 2 h. DNA damage was evaluated after 2 h of treatment. Following treatment, organoids were dissociated into single cells, embedded in low-melting-point agarose, and electrophoresed under alkaline conditions. Following electrophoresis, DNA migration patterns were visualized as comet structures under fluorescence microscopy and quantitatively analyzed using OpenComet software to determine the percentage of tail DNA (% Tail DNA). The comet assay successfully detected DNA damage in BCOs. Compared to the control group, BCOs exposed to 8 μM DOX for 2 h exhibited elongated comet tails following organoid dissociation and electrophoresis. Quantitative analysis revealed that the percentage of tail DNA was significantly higher in the treated group, indicating the induction of DNA damage. This highly sensitive method supports toxicological and pharmacodynamic studies of DOX and provides a robust technical platform for assessing DNA damage in patient-derived BCO systems.
- 26 June 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 232
Machine Learning-Based Identification of Tamoxifen Resistance-Associated Genes and Their Application in Prognostic Modeling of Breast Cancer
Tamoxifen is a key endocrine therapy for estrogen receptor-positive (ER+) breast cancer, but acquired resistance limits long-term efficacy. The molecular mechanisms remain complex, and predictive biomarkers are lacking. Gene expression data related to tamoxifen resistance were obtained from GEO (GSE67916), and differentially expressed genes (DEGs) were identified using the limma algorithm. Functional enrichment analyses (GO and KEGG) revealed involvement in immune processes, antiviral responses, endocytosis, lysosome pathways, and estrogen signaling. Three machine learning algorithms (LASSO, SVM-RFE, and RF) identified six hub genes (CAMK1D, CHAC1, KIAA0513, MED13, NDRG1, STXBP5). A prognostic risk model based on these genes was constructed using TCGA-BRCA data, effectively stratifying patients into high- and low-risk groups with significantly different overall survival. The model demonstrated good predictive accuracy (AUC = 0.70) and stable performance in time-dependent ROC analyses, validated in an independent cohort. This study provides a robust tamoxifen resistance-related gene signature and a multigene prognostic model, offering novel insights into resistance mechanisms and potential guidance for individualized prognosis and therapy in ER+ breast cancer.
- 26 June 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 232
Machine Learning-Based Identification of Tamoxifen Resistance-Associated Genes and Their Application in Prognostic Modeling of Breast Cancer
Tamoxifen is a key endocrine therapy for estrogen receptor-positive (ER+) breast cancer, but acquired resistance limits long-term efficacy. The molecular mechanisms remain complex, and predictive biomarkers are lacking. Gene expression data related to tamoxifen resistance were obtained from GEO (GSE67916), and differentially expressed genes (DEGs) were identified using the limma algorithm. Functional enrichment analyses (GO and KEGG) revealed involvement in immune processes, antiviral responses, endocytosis, lysosome pathways, and estrogen signaling. Three machine learning algorithms (LASSO, SVM-RFE, and RF) identified six hub genes (CAMK1D, CHAC1, KIAA0513, MED13, NDRG1, STXBP5). A prognostic risk model based on these genes was constructed using TCGA-BRCA data, effectively stratifying patients into high- and low-risk groups with significantly different overall survival. The model demonstrated good predictive accuracy (AUC = 0.70) and stable performance in time-dependent ROC analyses, validated in an independent cohort. This study provides a robust tamoxifen resistance-related gene signature and a multigene prognostic model, offering novel insights into resistance mechanisms and potential guidance for individualized prognosis and therapy in ER+ breast cancer.
- 26 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 944-963
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics
De novo purine synthesis is required to maintain tumor growth; however, its impact on therapy resistance remains unclear. Here, through a dynamic BH3-priming-based CRISPR screen, we found that deletion of ADSS2, which encodes the adenylosuccinate synthase 2 enzyme essential for adenosine monophosphate (AMP) synthesis, re-sensitizes drug-resistant acute myeloid leukemia cells to venetoclax and a myeloid cell leukemia-1 (MCL1) inhibitor. Single-cell sequencing analysis of patient-derived xenograft samples revealed a positive association of high ADSS2 activity in TP53-mutant cells with poor responsiveness to venetoclax. We developed an ADSS2 antagonist, which synergized with BH3 mimetics to promote apoptosis in preclinical models. Mechanistically, sensitization mediated by ADSS2 targeting correlated with downregulated AMP-activated protein kinase activity, which in resistant cells promotes mitophagy to eliminate damaged mitochondria after BH3 mimetic treatment. These data show that AMP synthesis promotes BH3 mimetic resistance and that combining ADSS2 targeting with BH3 mimetics represents a promising anti-cancer approach.
- 26 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 944-963
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics
De novo purine synthesis is required to maintain tumor growth; however, its impact on therapy resistance remains unclear. Here, through a dynamic BH3-priming-based CRISPR screen, we found that deletion of ADSS2, which encodes the adenylosuccinate synthase 2 enzyme essential for adenosine monophosphate (AMP) synthesis, re-sensitizes drug-resistant acute myeloid leukemia cells to venetoclax and a myeloid cell leukemia-1 (MCL1) inhibitor. Single-cell sequencing analysis of patient-derived xenograft samples revealed a positive association of high ADSS2 activity in TP53-mutant cells with poor responsiveness to venetoclax. We developed an ADSS2 antagonist, which synergized with BH3 mimetics to promote apoptosis in preclinical models. Mechanistically, sensitization mediated by ADSS2 targeting correlated with downregulated AMP-activated protein kinase activity, which in resistant cells promotes mitophagy to eliminate damaged mitochondria after BH3 mimetic treatment. These data show that AMP synthesis promotes BH3 mimetic resistance and that combining ADSS2 targeting with BH3 mimetics represents a promising anti-cancer approach.
- 23 June 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 232
Research Progress on DNA Damage Repair Efficiency Assessment Strategies
Cellular genomic DNA is continuously exposed to endogenous and exogenous factors that induce various forms of DNA damage. In mammalian cells, the daily burden of DNA damage may reach 104-105 lesions per cell. DNA damage that persists into the S phase can lead to mutations. When such mutations occur in oncogenes, tumor suppressor genes, or genes involved in cell proliferation, they may promote cellular transformation and carcinogenesis. Therefore, DNA damage repair plays a critical role in maintaining genomic stability and preventing cancer development. Assessment of DNA repair capacity is best achieved by measuring the functional activity of DNA repair systems. DNA damage repair pathways and their repair efficiencies are highly relevant to chemotherapeutic drug development, gene function validation, and cancer therapy. Accordingly, investigation of the repair efficiency of individual DNA damage repair pathways has important theoretical and practical significance. This review summarizes the major DNA damage repair pathways, methods used to assess repair efficiency, and the advantages and limitations of these approaches.
- 23 June 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 232
Research Progress on DNA Damage Repair Efficiency Assessment Strategies
Cellular genomic DNA is continuously exposed to endogenous and exogenous factors that induce various forms of DNA damage. In mammalian cells, the daily burden of DNA damage may reach 104-105 lesions per cell. DNA damage that persists into the S phase can lead to mutations. When such mutations occur in oncogenes, tumor suppressor genes, or genes involved in cell proliferation, they may promote cellular transformation and carcinogenesis. Therefore, DNA damage repair plays a critical role in maintaining genomic stability and preventing cancer development. Assessment of DNA repair capacity is best achieved by measuring the functional activity of DNA repair systems. DNA damage repair pathways and their repair efficiencies are highly relevant to chemotherapeutic drug development, gene function validation, and cancer therapy. Accordingly, investigation of the repair efficiency of individual DNA damage repair pathways has important theoretical and practical significance. This review summarizes the major DNA damage repair pathways, methods used to assess repair efficiency, and the advantages and limitations of these approaches.
- Open Access
- 22 May 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (5) , 47143
DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer
Breast cancer, characterized by distinctive epidemiological patterns and substantial heterogeneity, continues to be among the leading causes of cancer-related mortality in women. As breast tumors progressively acquire resistance to doxorubicin (DOX), DNA damage repair (DDR) pathways are recognized as key determinants of both DOX efficacy and the onset of resistance. Targeting DDR mechanisms in breast cancer patients with specific repair deficiencies offers the potential for personalized therapeutic approaches. This review first discusses the pivotal roles of five major DNA repair pathways (homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair) in the development of DOX resistance. This review aims to establish a theoretical framework and reference for future studies on DDR mechanisms in DOX-resistant breast cancer to advance intervention strategies for resistant breast tumors and to promote further research in this area.
- 22 May 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (5) , 47143
Open AccessDNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer
Breast cancer, characterized by distinctive epidemiological patterns and substantial heterogeneity, continues to be among the leading causes of cancer-related mortality in women. As breast tumors progressively acquire resistance to doxorubicin (DOX), DNA damage repair (DDR) pathways are recognized as key determinants of both DOX efficacy and the onset of resistance. Targeting DDR mechanisms in breast cancer patients with specific repair deficiencies offers the potential for personalized therapeutic approaches. This review first discusses the pivotal roles of five major DNA repair pathways (homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair) in the development of DOX resistance. This review aims to establish a theoretical framework and reference for future studies on DDR mechanisms in DOX-resistant breast cancer to advance intervention strategies for resistant breast tumors and to promote further research in this area.
- Open Access
- 19 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives
Background: Cancer immunotherapy has revolutionized the clinical management of cancer due to its promising survival benefits. Although FDA-approved cancer immunotherapy primarily leverages adaptive immunity for therapeutic efficacy, the critical role of innate immunity in tumor surveillance and eradication has been increasingly recognized. Recently, with the deepening of research in this field, macrophages have emerged as key effectors of the innate anti-tumor response, with antibody-dependent cellular phagocytosis (ADCP) becoming one of the primary mechanisms involved in cancer immunotherapy. As such, exploring ADCP-inducing monoclonal antibodies (mAbs) as forefront therapeutic regimens for patients with cancer is therefore highly sought after. Main body: Here, we broadly summarize recent translational advances in harnessing macrophage phagocytosis as a pivotal therapeutic approach in cancer immunotherapy, especially addressing how intravital imaging sheds light on ADCP in a real-time manner. Moreover, various challenges for targeting phagocytosis, strategies to enhance ADCP, and factors limiting its efficiency have also been summarized. We also investigated the potential of chimeric antigen receptor (CAR) macrophages as a next-generation therapeutic modality that bridges the innate and adaptive immune systems to induce robust anti-tumor immune responses. Conclusions: The insights presented in this review will set the scene for future investigations of possible alternative approaches that consider the antibody-dependent cellular phagocytosis for improved cancer immunotherapy.
- 19 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessAntibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives
Background: Cancer immunotherapy has revolutionized the clinical management of cancer due to its promising survival benefits. Although FDA-approved cancer immunotherapy primarily leverages adaptive immunity for therapeutic efficacy, the critical role of innate immunity in tumor surveillance and eradication has been increasingly recognized. Recently, with the deepening of research in this field, macrophages have emerged as key effectors of the innate anti-tumor response, with antibody-dependent cellular phagocytosis (ADCP) becoming one of the primary mechanisms involved in cancer immunotherapy. As such, exploring ADCP-inducing monoclonal antibodies (mAbs) as forefront therapeutic regimens for patients with cancer is therefore highly sought after. Main body: Here, we broadly summarize recent translational advances in harnessing macrophage phagocytosis as a pivotal therapeutic approach in cancer immunotherapy, especially addressing how intravital imaging sheds light on ADCP in a real-time manner. Moreover, various challenges for targeting phagocytosis, strategies to enhance ADCP, and factors limiting its efficiency have also been summarized. We also investigated the potential of chimeric antigen receptor (CAR) macrophages as a next-generation therapeutic modality that bridges the innate and adaptive immune systems to induce robust anti-tumor immune responses. Conclusions: The insights presented in this review will set the scene for future investigations of possible alternative approaches that consider the antibody-dependent cellular phagocytosis for improved cancer immunotherapy.
- 7 March 2026
- Published by MyJove Corporation
- No. 229,p. e69797
JoVE Video Dataset
Patients with primary refractory or relapsed acute myeloid leukemia (AML) typically face a poor prognosis. Current chemotherapy regimens do not always achieve complete remission (CR) before transplantation, while facing the dilemma of high organ toxicity and no chance of transplantation in some patients. A combination of cladribine, cytarabine, and venetoclax (CAV) represents a novel salvage regimen. In this study, cladribine, cytarabine, and venetoclax alone or in combination significantly inhibited the proliferation of leukemia cell lines and primary cells in a dose-dependent manner, with the triple CAV combination exerting a far stronger inhibitory effect than any single agent or dual-drug combination (p < 0.01) and showing synergistic interactions (combination index <1). Mechanistically, CAV exerts potent anti-AML effects by synergistically exacerbating DNA damage, inducing apoptosis, arresting the cell cycle at the G0/G1 phase, and promoting differentiation of AML cells toward myeloid/monocyte-macrophage lineages. Collectively, these findings confirm the efficacy of CAV and delineate its multifaceted mechanism of action, thereby providing a well-supported, mechanism-driven combinatorial therapeutic strategy for the management of AML.
- 7 March 2026
- Published by MyJove Corporation
- No. 229,p. e69797
JoVE Video Dataset
Patients with primary refractory or relapsed acute myeloid leukemia (AML) typically face a poor prognosis. Current chemotherapy regimens do not always achieve complete remission (CR) before transplantation, while facing the dilemma of high organ toxicity and no chance of transplantation in some patients. A combination of cladribine, cytarabine, and venetoclax (CAV) represents a novel salvage regimen. In this study, cladribine, cytarabine, and venetoclax alone or in combination significantly inhibited the proliferation of leukemia cell lines and primary cells in a dose-dependent manner, with the triple CAV combination exerting a far stronger inhibitory effect than any single agent or dual-drug combination (p < 0.01) and showing synergistic interactions (combination index <1). Mechanistically, CAV exerts potent anti-AML effects by synergistically exacerbating DNA damage, inducing apoptosis, arresting the cell cycle at the G0/G1 phase, and promoting differentiation of AML cells toward myeloid/monocyte-macrophage lineages. Collectively, these findings confirm the efficacy of CAV and delineate its multifaceted mechanism of action, thereby providing a well-supported, mechanism-driven combinatorial therapeutic strategy for the management of AML.